Fampridine is an active substance indicated to improve walking ability and multifactorial fatigue in adult patients with MS who have a walking disability (EDSS 4.0-7.0).
This program is intended for patients who:
Have multiple sclerosis (MS)
Present a significant walking impairment
Have sufficient capacity and motivation to actively participate in a physical rehabilitation program
A specific multidisciplinary rehabilitation program aimed at:
Improving walking function
Optimizing muscle strength and endurance
Optimizing fatigue management
The neurologist or specialist in physical and rehabilitation medicine prescribes fampridine at a dosage of 2 tablets per day, in accordance with current recommendations.
Depending on your needs, you will undergo a rehabilitation stay of 3 to 4 weeks and benefit from multidisciplinary care:
Multidisciplinary consultations for custom assistive devices are also offered, particularly for the provision of technical walking and mobility aids (for example, orthoses). Learn more.
The program includes standardized functional assessments carried out before, during, and after rehabilitation, making it possible to measure the impact of the treatment and care on walking, fatigue, and cognitive functions.
Our multidisciplinary team meets weekly to assess the patient’s progress.
The Fampyra treatment is covered by basic health insurance upon medical prescription.
Do not hesitate to discuss this with your doctor.
For any questions, Dr. Weaver is available by email at aweaverwetzel@cliniquevalmont.ch.
If you would like information about undertaking a rehabilitation stay at Clinique Valmont, our Admissions Department is available by phone at +41 21 962 37 40
